Ekterly
(Sebetralstat)PreclinicalSmall molecule
Ekterly is one of 23 small molecule programs targeting Angioedema. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
22
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
8
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Angioedema
#DrugCompanyPhaseTrials
1Firazyr
TakedaApproved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Xolair
RochePhase 3
Lanadelumab
TakedaPhase 3
Nacl
BayerPhase 3
Nucala
GGlaxo Dba Glaxosmithkline
Phase 2
DX-2930
TakedaPhase 3
Berinert
CSL BehringPhase 3
Conestat Alfa
UUniversity Hospital, Basel, Switzerland
Phase 3
KALBITOR
TakedaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Angioedema2 trials
Regulatory
FDA Approval Timeline[4]
Jul 3, 2025
EKTERLY
NDA NDA219301
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sebetralstat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- KKalVista Pharmaceuticals, Ltd.